Cardiometabolic phenotype‐associated genes, like SCRN1, is a candidate biomarker for AD, reflecting tau pathology; APOE, is a major apoprotein of the chylomicron, functioning in the catabolism of triglyceride rich lipoproteins and lipoprotein mediated lipid transport, and is the well‐known genetic risk factor for AD; and FZD9, contributes to neuromuscular junction assembly by inhibiting the clustering of acetylcholine receptors via the beta‐catenin canonical signaling pathway. This evidence concerns the gene FZD9 and Alzheimer disease.